Aliases & Classifications for Pituitary Tumors

MalaCards integrated aliases for Pituitary Tumors:

Name: Pituitary Tumors 55 56 44
Pituitary Neoplasms 74

External Ids:

UMLS 74 C0032019

Summaries for Pituitary Tumors

NINDS : 55 The pituitary is a small, bean-sized gland that is below the hypothalamus, a structure at the base of the brain, by a thread-like stalk that contains both blood vessels and nerves.  It controls a system of hormones in the body that regulate growth, metabolism, the stress response, and functions of the sex organs via the thyroid gland, adrenal gland, ovaries, and testes.  A pituitary tumor is an abnormal growth of cells within the pituitary gland.  Most pituitary tumors are benign, which means they are non-cancerous, grow slowly and do not spread to other parts of the body; however they can make the pituitary gland produce either too many or too few hormones, which can cause problems in the body. Tumors that make hormones are called functioning tumors, and they can cause a wide array of symptoms depending upon the hormone affected.  Tumors that don’t make hormones are called non-functioning tumors.  Their symptoms are directly related to their growth in size and include headaches, vision problems, nausea, and vomiting.  Diseases related to hormone abnormalities include Cushing’s disease, in which fat builds up in the face, back and chest, and the arms and legs become very thin; and acromegaly, a condition in which the hands, feet, and face are larger than normal.  Pituitary hormones that impact the sex hormones, such as estrogen and testosterone, can make a woman produce breast milk even though she is not pregnant or nursing, or cause a man to lose his sex drive or lower his sperm count.  Pituitary tumors often go undiagnosed because their symptoms resemble those of so many other more common diseases.

MalaCards based summary : Pituitary Tumors, also known as pituitary neoplasms, is related to prolactin producing pituitary tumor and tsh producing pituitary tumor. An important gene associated with Pituitary Tumors is GNAS (GNAS Complex Locus), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Dexmedetomidine and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and thyroid, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

MedlinePlus : 44 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. Pituitary tumors are common, but often they don't cause health problems. Most people with pituitary tumors never even know they have them. The most common type of pituitary tumor produces hormones and disrupts the balance of hormones in your body. This can cause endocrine diseases such as Cushing's syndrome and hyperthyroidism. Symptoms of pituitary tumors include Headaches Vision problems Nausea and vomiting Problems caused by the production of too many hormones Pituitary tumors are usually curable. Treatment is often surgery to remove the tumor. Other options include medicines, radiation therapy, and chemotherapy.

Related Diseases for Pituitary Tumors

Diseases related to Pituitary Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 34.0 PRL SST
2 tsh producing pituitary tumor 33.2 GH1 POMC PRL SST
3 acth-secreting pituitary adenoma 32.2 POMC PRL
4 gigantism 32.1 AIP GH1 PRL
5 pituitary apoplexy 32.0 AIP POMC PRL
6 empty sella syndrome 31.9 GH1 IGF1 POMC PRL
7 pituitary adenoma 1, multiple types 31.7 AIP GH1 IGF1 PRL SST
8 hormone producing pituitary cancer 31.3 AIP GNAS IGF1 MEN1 SST SSTR5
9 galactorrhea 30.7 IGF1 PRL
10 hyperthyroidism 30.1 GH1 GNAS PRL SST
11 ovarian disease 30.0 IGF1 PRL VEGFA
12 multiple endocrine neoplasia, type i 30.0 GNAS MEN1 PRL SST
13 non-functioning pituitary adenoma 30.0 GH1 SST
14 thyroid cancer 29.9 GNAS POMC SST VEGFA
15 lymphocytic hypophysitis 29.9 GH1 POMC
16 hyperprolactinemia 29.9 GH1 IGF1 POMC PRL SST
17 insulin-like growth factor i 29.8 GH1 IGF1 PRL SST
18 adenohypophysitis 29.7 GH1 POMC PRL
19 small cell cancer of the lung 29.6 POMC RB1 SST
20 meningioma, familial 29.6 MEN1 SST VEGFA
21 chiasmal syndrome 29.5 POMC PRL SST
22 pituitary carcinoma 29.5 POMC PRL SST
23 nelson syndrome 29.5 POMC PRL SST
24 conn's syndrome 29.5 GH1 GNAS MEN1 POMC PRL SST
25 mccune-albright syndrome 29.5 GH1 GNAS IGF1 PRL SST
26 pituitary hypoplasia 29.4 POU1F1 PRL
27 carney complex variant 29.4 AIP GNAS MEN1
28 pituitary gland disease 29.1 AIP GH1 IGF1 MEN1 POMC POU1F1
29 craniopharyngioma 29.0 GH1 IGF1 POU1F1 PRL PROP1
30 thyroid carcinoma, familial medullary 28.9 MEN1 POMC SST SSTR5
31 hypopituitarism 28.7 GH1 IGF1 POMC POU1F1 PRL PROP1
32 acromegaly 28.5 AIP GH1 GNAS IGF1 MEN1 POMC
33 functioning pituitary adenoma 28.4 GH1 MEN1 POMC PRL SST SSTR5
34 hypothyroidism 28.4 GH1 GNAS IGF1 POMC POU1F1 PRL
35 pituitary hormone deficiency, combined, 2 28.4 GH1 IGF1 POMC POU1F1 PRL PROP1
36 adenoma 28.2 AIP GH1 GNAS IGF1 MEN1 POMC
37 pituitary adenoma, prolactin-secreting 28.1 AIP GH1 GNAS IGF1 MEN1 POMC
38 secondary adrenal insufficiency 11.3
39 posterior pituitary gland neoplasm 11.1
40 acth-independent macronodular adrenal hyperplasia 11.0
41 primary pigmented nodular adrenocortical disease 11.0
42 fibrous dysplasia/mccune-albright syndrome 10.4 GH1 PRL
43 chronic mountain sickness 10.3 SST VEGFA
44 angiodysplasia 10.3 SST VEGFA
45 ovarian cyst 10.3 PRL VEGFA
46 villous adenoma 10.3 GNAS SST
47 central precocious puberty 10.3 GH1 IGF1
48 mammographic density 10.3 IGF1 PRL
49 marasmus 10.3 GH1 IGF1
50 spinocerebellar degeneration 10.3 PRL SST

Graphical network of the top 20 diseases related to Pituitary Tumors:



Diseases related to Pituitary Tumors

Symptoms & Phenotypes for Pituitary Tumors

MGI Mouse Phenotypes related to Pituitary Tumors:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.22 AIP GNAS IGF1 MEN1 POMC POU1F1
2 homeostasis/metabolism MP:0005376 10.21 AIP GNAS IGF1 MEN1 POMC POU1F1
3 growth/size/body region MP:0005378 10.2 AIP GNAS IGF1 MEN1 POMC POU1F1
4 cellular MP:0005384 10.1 AIP GNAS IGF1 MEN1 POMC POU1F1
5 immune system MP:0005387 10.06 GNAS IGF1 MEN1 POMC POU1F1 PRL
6 mortality/aging MP:0010768 9.96 AIP GNAS IGF1 MEN1 POMC POU1F1
7 integument MP:0010771 9.91 AIP GNAS IGF1 POMC PRL RB1
8 liver/biliary system MP:0005370 9.87 AIP GNAS MEN1 POMC PRL RB1
9 neoplasm MP:0002006 9.76 AIP GNAS IGF1 MEN1 POMC PRL
10 nervous system MP:0003631 9.65 GNAS IGF1 MEN1 POMC POU1F1 PRL
11 reproductive system MP:0005389 9.17 IGF1 MEN1 POU1F1 PRL PROP1 RB1

Drugs & Therapeutics for Pituitary Tumors

Drugs for Pituitary Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 5311068 68602
2
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
6
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 6400441 383414
11
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
12
Pasireotide Approved Phase 4,Phase 3,Phase 2 396091-73-9 9941444
13
Liraglutide Approved Phase 4 204656-20-2 44147092
14
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
15
Zinc Approved, Investigational Phase 4 7440-66-6 32051
16
leucovorin Approved Phase 4,Phase 1 58-05-9 143 6006
17
lanreotide Approved Phase 4,Phase 3 108736-35-2
18
Cefazolin Approved Phase 4 25953-19-9 33255 656510
19
Cefdinir Approved Phase 4 91832-40-5 6915944
20
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
21
Sulfamethoxazole Approved Phase 4 723-46-6 5329
22
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
23
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
25
Lactitol Investigational Phase 4,Phase 3 585-88-6, 585-86-4 493591
26 Adrenergic Agents Phase 4,Not Applicable
27 Adrenergic Agonists Phase 4,Not Applicable
28 Analgesics, Non-Narcotic Phase 4,Not Applicable
29 Hydrocortisone hemisuccinate Phase 4,Phase 3,Phase 2,Not Applicable
30 Adrenergic alpha-2 Receptor Agonists Phase 4,Not Applicable
31 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1,Not Applicable
32 Anesthetics Phase 4,Phase 1,Not Applicable
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Adrenergic alpha-Agonists Phase 4,Not Applicable
35 Hypnotics and Sedatives Phase 4,Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
38 Analgesics Phase 4,Not Applicable
39 Hydrocortisone-17-butyrate Phase 4,Not Applicable
40 Central Nervous System Depressants Phase 4,Phase 1,Not Applicable
41 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2,Not Applicable
42 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Narcotics Phase 4,Not Applicable
48 Analgesics, Opioid Phase 4,Not Applicable
49 Incretins Phase 4,Not Applicable
50 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
2 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
3 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
4 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
5 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
6 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
7 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
8 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
9 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
10 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
11 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
12 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
13 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
14 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
15 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
16 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
17 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
18 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
19 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
20 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
21 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
22 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
23 Prevention of Metabolic Complications of Glucocorticoid Excess Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
24 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
25 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
26 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
27 Open-label Treatment in Cushing's Syndrome Recruiting NCT03621280 Phase 3 Levoketoconazole
28 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
29 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699;LCI699 matching placebo
30 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
31 Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Terminated NCT00642421 Phase 3 C2L-OCT-01 PR, 10 or 20 mg;C2L-OCT-01 PR, 20 mg
32 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
33 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
34 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
35 Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
36 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
37 Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
38 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities Completed NCT00054756 Phase 2 TRH (Thyrotropin Releasing Hormone)
39 Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Completed NCT01283542 Phase 2 Pasireotide LAR
40 Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Completed NCT00697814 Phase 2 Clomiphene citrate
41 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
42 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
43 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
44 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
45 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
46 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
47 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
48 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Active, not recruiting NCT02749227 Phase 2 Pasireotide LAR
49 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
50 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.

Search NIH Clinical Center for Pituitary Tumors

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Pituitary Tumors

Anatomical Context for Pituitary Tumors

MalaCards organs/tissues related to Pituitary Tumors:

42
Pituitary, Brain, Thyroid, Testes, Hypothalamus, Ovary, Adrenal Gland

Publications for Pituitary Tumors

Articles related to Pituitary Tumors:

(show top 50) (show all 1059)
# Title Authors Year
1
Utilization of the Nasoseptal Flap for Repair of Cerebrospinal Fluid Leak after Endoscopic Endonasal Approach for Resection of Pituitary Tumors. ( 31062526 )
2019
2
Advances and controversies in the classification and grading of pituitary tumors. ( 29858984 )
2019
3
Endoscopic Endonasal Approach Combined with a Simultaneous Transcranial Approach for Giant Pituitary Tumors. ( 30336293 )
2019
4
Variability in Clinical Presentation and Pathologic Implications of Ectopic Pituitary Tumors: Critical Review of Literature. ( 30404064 )
2019
5
Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey. ( 30456434 )
2019
6
Predictive Factors for Delayed Hyponatremia After Endoscopic Transsphenoidal Surgery in Patients with Nonfunctioning Pituitary Tumors: A Retrospective Observational Study. ( 30465961 )
2019
7
Use of intraoperative intracavitary (direct-contact) ultrasound for resection control in transsphenoidal surgery for pituitary tumors: evaluation of a microsurgical series. ( 30483982 )
2019
8
Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance). ( 30531551 )
2019
9
Long-term survival with stereotactic radiotherapy for imaging-diagnosed pituitary tumors in dogs. ( 30575174 )
2019
10
Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. ( 30589642 )
2019
11
Application of indocyanine green fluorescence endoscopic system in transsphenoidal surgery for pituitary tumors. ( 30762125 )
2019
12
Recovery Room Cortisol Predicts Long-Term Glucocorticoid Need After Transsphenoidal Surgery for Pituitary Tumors. ( 30767017 )
2019
13
Correlation of MRI Findings With Patterns of Visual Field Loss in Patients With Pituitary Tumors. ( 30807381 )
2019
14
Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. ( 30867568 )
2019
15
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience. ( 30939449 )
2019
16
Propofol Requirement in Patients with Growth Hormone-Secreting Pituitary Tumors Undergoing Transsphenoidal Surgery. ( 31035466 )
2019
17
The risk/benefit ratio of radiotherapy in pituitary tumors. ( 31053487 )
2019
18
RPSAP52 lncRNA is overexpressed in pituitary tumors and promotes cell proliferation by acting as miRNA sponge for HMGA proteins. ( 31076808 )
2019
19
Clinical Presentation and Management of Headache in Pituitary Tumors. ( 29904889 )
2018
20
Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications. ( 28711607 )
2018
21
Transsphenoidal Surgery for Pituitary Tumors and Other Sellar Masses. ( 29056398 )
2018
22
Excellence in the treatment of patients with pituitary tumors. ( 29124563 )
2018
23
Non-functioning pituitary tumors: any special considerations during pregnancy? ( 29265782 )
2018
24
Prognostic factors of regrowth in nonfunctioning pituitary tumors. ( 29288467 )
2018
25
Baculovirus-based gene silencing of Humanin for the treatment of pituitary tumors. ( 29352443 )
2018
26
Management of nonfunctioning pituitary tumors: radiotherapy. ( 29372392 )
2018
27
Genomic Alterations in Sporadic Pituitary Tumors. ( 29396598 )
2018
28
Expression of Matrix Metalloproteinase-9, Pituitary Tumor Transforming Gene, High Mobility Group A 2, and Ki-67 in Adrenocorticotropic Hormone-Secreting Pituitary Tumors and Their Association with Tumor Recurrence. ( 29432944 )
2018
29
Endoscopic Endo-Nasal Trans-Sphenoidal Excision of Pituitary Tumors: An Institutional Experience. ( 29456951 )
2018
30
Leptin Involvement in Primary Brain and Pituitary Tumors: Therapeutic Potential, Prognostic Value, and Proposed Diagnostic Application. ( 29464548 )
2018
31
Welcoming the new WHO classification of pituitary tumors 2017: revolution in TTF-1-positive posterior pituitary tumors. ( 29500747 )
2018
32
Dysregulation of cell cycle in animal models and human neuroendocrine pituitary tumors (PitNET). ( 29504817 )
2018
33
65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update. ( 29535142 )
2018
34
The role of galectin-3 in the tumorigenesis and progression of pituitary tumors. ( 29545898 )
2018
35
Detection of circulating tumor cells in patients with pituitary tumors. ( 29587659 )
2018
36
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. ( 29963012 )
2018
37
Headaches in Patients with Pituitary Tumors: a Clinical Conundrum. ( 29974273 )
2018
38
Lnc-SNHG1 Activates the TGFBR2/SMAD3 and RAB11A/Wnt/β-Catenin Pathway by Sponging MiR-302/372/373/520 in Invasive Pituitary Tumors. ( 30048990 )
2018
39
Three-Dimensional Volumetric Segmentation of Pituitary Tumors: Assessment of Inter-rater Agreement and Comparison with Conventional Geometric Equations. ( 30210975 )
2018
40
Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. ( 30246233 )
2018
41
The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. ( 30273935 )
2018
42
Effectiveness of intraoperative visual evoked potential in avoiding visual deterioration during endonasal transsphenoidal surgery for pituitary tumors. ( 30288662 )
2018
43
Medical therapy for non-functioning pituitary tumors-a critical approach. ( 30368687 )
2018
44
Evaluation of bendable surgical suction devices made of shape-memory alloy for the endonasal transsphenoid removal of pituitary tumors. ( 30540892 )
2018
45
Association between intravenous acetaminophen and reduction in intraoperative opioid consumption during transsphenoidal surgery for pituitary tumors. ( 30787509 )
2018
46
MicroRNA‑16/VEGFR2/p38/NF‑κB signaling pathway regulates cell growth of human pituitary neoplasms. ( 29399695 )
2018
47
First Report of Coexistence of Two Ectopic Pituitary Tumors: Rathke Cleft Cyst and Silent Adrenocorticotropic Hormone Adenoma. ( 28532906 )
2017
48
Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort. ( 28938458 )
2017
49
FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. ( 27966451 )
2017
50
MicroRNAs in pituitary tumors. ( 28089822 )
2017

Variations for Pituitary Tumors

Expression for Pituitary Tumors

Search GEO for disease gene expression data for Pituitary Tumors.

Pathways for Pituitary Tumors

GO Terms for Pituitary Tumors

Cellular components related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 GH1 GNAS IGF1 POMC PRL SST
2 endosome lumen GO:0031904 9.16 GH1 PRL
3 chromatin GO:0000785 9.13 MEN1 POU1F1 RB1
4 secretory granule GO:0030141 8.62 POMC VEGFA

Biological processes related to Pituitary Tumors according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 MEN1 POU1F1 PROP1 RB1 VEGFA
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.61 GH1 IGF1 VEGFA
3 regulation of multicellular organism growth GO:0040014 9.57 IGF1 PRL
4 positive regulation of JAK-STAT cascade GO:0046427 9.56 GH1 PRL
5 positive regulation of receptor internalization GO:0002092 9.55 GH1 VEGFA
6 negative regulation of cell proliferation GO:0008285 9.55 MEN1 POU1F1 RB1 SST SSTR5
7 tissue homeostasis GO:0001894 9.54 GNAS RB1
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 GH1 IGF1 VEGFA
9 myoblast differentiation GO:0045445 9.52 IGF1 RB1
10 positive regulation of transcription by RNA polymerase II GO:0045944 9.5 IGF1 MEN1 POMC POU1F1 PROP1 RB1
11 positive regulation of transcription regulatory region DNA binding GO:2000679 9.49 IGF1 RB1
12 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.48 GH1 PRL
13 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 GH1 IGF1
14 adenohypophysis development GO:0021984 9.4 POU1F1 PROP1
15 positive regulation of epithelial cell proliferation GO:0050679 9.32 IGF1 VEGFA
16 somatotropin secreting cell differentiation GO:0060126 9.26 POU1F1 PROP1
17 regulation of signaling receptor activity GO:0010469 9.1 GH1 IGF1 POMC PRL SST VEGFA

Molecular functions related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 GH1 IGF1 VEGFA
2 insulin-like growth factor receptor binding GO:0005159 9.16 GNAS IGF1
3 hormone activity GO:0005179 9.02 GH1 IGF1 POMC PRL SST
4 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Pituitary Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....